A new study of Roche's Avastin has shown the drug can extend progression-free survival (PFS) by more than four months when added onto standard therapy for an aggressive form of brain cancer. The AVAgl…
Combining two novel GlaxoSmithKline drugs the selective BRAF inhibitor dabrafenib and the selective MAPK kinase MEK inhibitor trametinib significantly improved progressionfree survival in a Phase II s…
Roche has reported that the phase III AVAglio study of Avastin plus radiation and temozolomide chemotherapy in people with newly diagnosed glioblastoma met its coprimary endpoint of a significant impr…
